Relevant facts to the Stock Exchange

Oryzon Genomics, S.A. places at your disposal all of the relevant information in line with that sent to the Spanish National Securities Market Commission (CNMV) and published on its website. Please register for the e-mail alert service if you wish to be notified when a new event is added.

2019

9 Diciembre 2019

Oryzon presents new positive efficacy data of iadademstat from the Phase IIa ALICE trial in AML

25 Octubre 2019

Q3 2019 Financial Results CNMV format (Spanish only) Publication of the Company‘s Results’ Information for the Third Quarter 2019

3 Octubre 2019

Oryzon presents new positive efficacy data of vafidemstat in the treatment of aggression from the Phase IIa REIMAGINE trial

30 Septiembre 2019

Oryzon presenta resultados adicionales de eficacia de iadademstat de su ensayo de Fase IIa CLEPSIDRA en cáncer de pulmón de célula pequeña Oryzon presents additional iadademstat efficacy results from the CLEPSIDRA Phase IIa trial in small cell lung cancer

10 Septiembre 2019

Oryzon presents vafidemstat efficacy data from the REIMAGINE Phase IIa trial’s Autism Spectrum Disorder (ASD) cohort

9 Septiembre 2019

ORYZON presents preliminary efficacy data from the first patient from its iadademstat’s Phase IIa CLEPSIDRA clinical trial in small cell lung cancer at the 20th World Conference on Lung Cancer

30 Julio 2019

Q2 2019 Financial Results CNMV format ( Spanish only) Oryzon Q2 2019 Financial Results ( Spanish only)

26 Julio 2019

The Company announces that the public deed relating to the share capital increase has been duly registered with the Commercial Registry and that the new shares have been admitted to trading

25 Julio 2019

The company announces the result of the accelerated bookbuild offering

24 Julio 2019

The company announces a capital increase through an accelerated bookbuild offering

16 Julio 2019

ORYZON announces that data from its ETHERAL Phase IIa clinical trial of vafidemstat in Alzheimer’s patients were presented yesterday at the Alzheimer´s Association International Conference (AAIC-2019)

14 Junio 2019

Oryzon presents iadademstat preliminary efficacy data from the ALICE Phase IIa trial in acute myeloid leukemia

17 Mayo 2019

Information on the resolutions approved at the Annual General Meeting of Shareholders on May 13, 2019 (Spanish only)

13 Mayo 2019

Publication of the Company‘s Results’ Information for the First Quarter 2019 Q1 2019 Financial Results CNMV format ( Spanish only)

25 Abril 2019

Oryzon presents vafidemstat efficacy data from the REIMAGINE Phase IIa trial’s Attention Deficit Hyperactivity Disorder (ADHD) cohort

9 Abril 2019

Call of the Ordinary General Shareholders’ Meeting of Oryzon Genomics, S.A.

8 Abril 2019

Oryzon presents vafidemstat efficacy data from the REIMAGINE Phase II trial’s Borderline Personality Disorder cohort at the 27th European Congress of Psychiatry (EPA 2019)

20 Marzo 2019

Oryzon to present topline preliminary results on Vafidemstat’s Reimagine Phase IIa trial on the cohort of Borderline Personality Disorder

11 Marzo 2019

Approval by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug application (IND) for ETHERAL, a PhIIa clinical trial of vafidemstat (ORY-2001)

15 Febrero 2019

The company sends press release about 2018 Financial Results (Spanish) Publication of the Company’s Annual Director Remuneration Report for year 2018 (Spanish) Corporate Governance Annual Report 2018 (Spanish) Publication of the Company‘s Results’ Information for the second semester 2018 (Spanish)